8 May 2003

Investment in investor relations helps up round

In providing investor relations counsel to its clients, Northbank advises that companies build relationships with potential investors well ahead of any funding need and keep them informed of company progress – thus creating an audit trail creating confidence that the management is delivering on its promises and creating value. The recent upround achieved by Cytokinetics, demonstrates the value of such an approach, as reported in BioCentury…

"The Company has made a conscious effort over the years to benchmark its rapid progress from biology to products, giving both existing and potential investors confidence that management is executing its business plan' reports Kathryn Calkins.

"Cytokinetics has invested in building relationships with investors who were not prepared to come in at earlier stages of the company's development. Many companies don't nurture those relationships, so they have to introduce the company when the time comes' noted Robert Blum, CFO of Cytokinetics.

Andreas Wicki, partner with HBM Bioventures, an investor agrees 'It is much easier if you've seen a company over three or four or five years. You can see they have executed, which builds trust'.

As fund raising conditions remain harsh and down rounds become the norm, an investment in proactive, forward looking investor relations can pay dividends.

back to news

© 2007 College Hill Associates | Registered in England No 1036926 / VAT No 245666930 | Legal